Edition:
United States

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.83USD
15 Jun 2018
Change (% chg)

$-0.02 (-2.13%)
Prev Close
$0.85
Open
$0.85
Day's High
$0.85
Day's Low
$0.83
Volume
22,802
Avg. Vol
43,245
52-wk High
$2.83
52-wk Low
$0.78

Chart for

About

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $18.67
Shares Outstanding(Mil.): 22.01
Dividend: --
Yield (%): --

Financials

  DMPI.OQ Industry Sector
P/E (TTM): -- 28.41 19.98
EPS (TTM): -0.65 -- --
ROI: -252.92 4.43 0.56
ROE: -- 5.89 16.45

BRIEF-Delmar Appoints Saiid Zarrabian Full-Time President And CEO

* DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO

May 22 2018

BRIEF-DelMar Pharmaceuticals Reports Q3 Loss Per Share Of $0.13

* DELMAR PHARMACEUTICALS ANNOUNCES THIRD QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

May 17 2018

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

Apr 17 2018

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

Apr 13 2018

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

Feb 14 2018

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

Dec 26 2017

Competitors

  Price Chg
Gilead Sciences, Inc. (GILD.OQ) $70.23 -0.92
Celgene Corporation (CELG.OQ) $78.08 -0.31
Exelixis, Inc. (EXEL.OQ) $19.64 +0.24

Earnings vs. Estimates